Neuland Laboratories Ltd Q1 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/fn46rxlnqzik59n9dog5fi12.pdf

Key Takeaways


Revenue Lumpiness & the Quarter

Davuluri: "I think even if you look at the last 4-5 years journey of Neuland, I think some of the biggest contributors for lumpiness have been the scale-ups or the gaps in production of our specialty and CMS molecules."

CMS Pipeline & Capacity

Davuluri: "An innovator ideally tries to place a molecule in Phase-2, early Phase-2, and expects the CDMO to take the molecule through commercial launch. It is only when there is some sort of a bottleneck or a setback on the manufacturing front does the innovator pivot to a new CDMO in Phase-3."

GDS & Specialty Portfolio

Davuluri: "Just having infrastructure may not be enough."

Big Pharma & New Business

Davuluri: "Neuland is in contact with several Big Pharma for areas of peptides or deuterated molecules because these are capabilities that Big Pharma does not find from their traditional API suppliers."

Margins & Working Capital


COPD Drug & Long-Term Bets

Davuluri: "Evaluating Neuland's trajectory on a 3-year block basis is likely to be more accurate than comparing a QoQ or a YoY basis."

Guidance & Commitments

CommitmentSpecificsTimeline
FY26 growth trajectoryResume growth on the FY24 base despite weak Q1 startFY26 full year
CMS molecule commercializationOne more molecule to be commercializedDuring FY26
Unit 3 production blockCommercial production to begin, driving H2 revenue momentumLater this fiscal year
Peptide facility completionNew dedicated peptide facility to be completedNext financial year (FY27)
COPD drug commercializationDrug just entering Phase-3 nowA couple of years away
Lumpiness reductionQuarterly variability to come down as commercialized product base scales2-3 years
Margin recoveryMargins to recover as sales ramp, comparable to FY24 levelsDuring FY26

Key Metrics

MetricQ1 FY26
Total income₹300.6 cr, down 32.4% YoY from ₹444 cr in Q1 FY25
Gross margin55.3%, vs 56.1% in Q1 FY25
Profit after tax₹13.7 cr, vs ₹98.3 cr in Q1 FY25
EPS₹10.7 per share
CMS revenue share~44% of total revenue
Working capital145 days of sales
Free cash flownegative ₹66 cr
Net debtnegative ₹165 cr (net cash)
CAPEX for the quarter₹79 cr cash outflow
CAPEX guidance for FY26~₹250 cr, split 60% growth and 40% maintenance
CMS pre-registration molecules8, down from 9 due to a dropped intermediate
CMS Phase-3 molecules1 new addition this quarter
FY24 EBITDA margin30% or upwards, described as exceptional